Pilot Study of the ARTUS® Artificial Urinary Sphincter on Women (SPHIN-X)
Pilot Clinical Investigation of the ARTUS® Artificial Urinary SPHincter (AUS) for the Treatment of Stress UrInary iNcontinence (SUI) in Women
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Jean-Christophe PERLES
- Número de telefone: +33 04 42 95 12 20
- E-mail: jcperles@carvolix.eu
Estude backup de contato
- Nome: Federica Azzimonti
- E-mail: federica.azzimonti@carvolix.eu
Locais de estudo
-
-
-
Paris, França
- Cochin Hospital, APHP
-
Contato:
- Nicolas Barry Delonghchamps, MD, PHD
- Número de telefone: +33 1 58 41 27 83
- E-mail: nicolas.barry-delongchamps@aphp.fr
-
Paris, França
- Tenon Hospital, APHP
-
Contato:
- Véronique Phé, MD, PHD
- Número de telefone: +33 01 56 01 70 00
- E-mail: veronique.phe@aphp.fr
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Female subject over 18 years of age at the time of consent signature
Subject with persistent severe urinary incontinence:
- at least 3 months after failed pelvic floor muscle training OR
- at least 6 months after a failed surgical treatment (e.g. slings)
- Subject with severe Stress Urinary Incontinence, defined as a mean value of 3 consecutive 24-hour Pad Weight Test > 100 grams
- Subject willing and able to provide written informed consent and having signed the informed consent
- Subject having understood and accepted to be unable to proceed to an MRI examination after the surgical procedure due to the non-MRI compatibility of the device
- Subject having a life expectancy ≥ 5 years as assessed by the investigator
Exclusion Criteria:
- Subject currently enrolled or plans to participate in another investigational study of a drug, biologic, or medical device from the point of enrolment through the 12 months post device activation period
- Subject deprived of liberty by administrative or judicial decision or under legal guardianship
- Subject who is unwilling or deemed by the investigator to be unwilling to comply with the clinical study requirements, including attending follow-up visits.
- Subject having inadequate cognitive or capabilities to use the Artus device as assessed by the investigator
- Pregnant subject, or subject willing to be pregnant during the study duration, or subject of child-bearing potential with non-stable medication contraception
- Subject with urge incontinence due to hyperactive bladder not adequately controlled by drug therapy
- Subject with overflow urinary incontinence
- Subject with Significant Neuro-urological disorders: elevated detrusor pressure, Detrusor sphincter desinergy
- Subject with history of pelvic radiotherapy
- Subject with any planned procedure requiring urethral catheterization 12 months after implant procedure (include intermittent catheterization) except for diagnostic purposes
- Subject with known allergy to any components of the device
- Subject with history of Artificial Urinary Sphincter
- Subject with severe congenital or acquired haemorrhagic disease, haemophilia, or another coagulopathy
- Subject under anti-coagulation or anti-platelet medication that cannot be discontinued at least 5 days prior to surgery and restarted at least 5 days after surgery
- Subject having a Body Mass Index (BMI) > 40
- Subject with uncontrolled diabetes, defined as HbA1c > 9.0% within the past 6 months
- Subject with history of urethral fistula
- Subject with history of bladder tumor
- Subject with severe urethral stenosis.
- Subject with currently active infection, including urinary tract infection
- Subject with severe renal failure or obstructive pathologies of the upper urinary tract with severe renal failure
- Subject with congenital or acquired immunodeficiency, including those who are immunocompromised or immunosuppressed
- Subject with post void residual volume greater than 200 mL within the past 6 months
- Subject with history of recurrent bladder stones or history of failed bladder stone treatment within the past 12 months
- Subject in emergency situation (caused by a sudden life threatening or other sudden serious medical condition including but not limited to heart attack, stroke, coma, epileptic seizure, heavy bleeding, severe pain, trouble breathing…)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: ARTUS
The subjects will be implanted with the ARTUS Artificial Urinary Sphincter to treat Stress Urinary Incontinence
|
The subjects will be implanted by the ARTUS Artificial Urinary Sphincter (AUS).
The device will be activated 6 weeks after surgery and the tightening will be adjusted by the investigators in order to reach continence.
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Adverse Device Effect Incidence
Prazo: 3 months after implantation
|
all adverse device effects (device and/or procedure related) occurring from the implantation up to the 3 months post-operative visit, with their occurrence, severity, and nature.
These events will be analyzed and classified using the Clavien-Dindo classification grading system.
|
3 months after implantation
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Adverse Events Incidence
Prazo: Day 30, 3 months, 6 months, 12 months and 24 months after implantation
|
all adverse events (including adverse device effect) occurring peri-operatively, 30 days after implantation and at 3, 6, 12 and 24-months post-operative with their occurrence, severity, and nature.
All adverse events will be analyzed and classified using the Clavien-Dindo classification grading system
|
Day 30, 3 months, 6 months, 12 months and 24 months after implantation
|
|
Revision Rate
Prazo: 30 days, 3 months, 6 months, 12 months and 24 months after implantation
|
Proportion of subjects with a revision of the Artificial Urinary Sphincter
|
30 days, 3 months, 6 months, 12 months and 24 months after implantation
|
|
Explantation Rate
Prazo: Day 30, 3 months, 6 months, 12 months and 24 months after implantation
|
Proportion of subjects with a definitive explantation of the Artificial Urinary Sphincter
|
Day 30, 3 months, 6 months, 12 months and 24 months after implantation
|
|
Evolution of Renal Function
Prazo: Baseline, Day 1
|
Measure of the serum creatinine
|
Baseline, Day 1
|
|
Evolution of the pain
Prazo: Day 1, Day 45, 3 months, 6 months, 12 months and 24 months after implantation
|
Measure of the pain using a 10-point numerical scale (from 0 no pain to 10 the maximum pain)
|
Day 1, Day 45, 3 months, 6 months, 12 months and 24 months after implantation
|
|
Evolution of uroflowmetry
Prazo: Baseline, 3 months after implantation
|
measure of the voided urine per unit of time, the voided volume and the maximum flow rate
|
Baseline, 3 months after implantation
|
|
Bladder Drainage
Prazo: Baseline, Day 1, 3 months, 6 months, 12 months and 24 months after implantation
|
measure of the post-void residual volume
|
Baseline, Day 1, 3 months, 6 months, 12 months and 24 months after implantation
|
|
Device Deficiency
Prazo: Implantation, Day 1, Day 45, 3 months, 6 months, 12 months, 24 months after implantation
|
Number of device deficiencies
|
Implantation, Day 1, Day 45, 3 months, 6 months, 12 months, 24 months after implantation
|
|
Pad Weight Test
Prazo: Baseline, 3 months, 6 months, 12 months and 24 months after implantation
|
Measure of the daily urine loss in pads during 3 consecutive days
|
Baseline, 3 months, 6 months, 12 months and 24 months after implantation
|
|
Pads Usage
Prazo: Baseline, Day 45, 3 months, 6 months, 12 months and 24 months after -implantation
|
Number of pads used per day
|
Baseline, Day 45, 3 months, 6 months, 12 months and 24 months after -implantation
|
|
Evolution of Stress Urinary Symptoms
Prazo: Baseline, 3 months, 6 months, 12 months and 24 months after implantation
|
Evolution of the International Consultation on Incontinence Questionnaire - Urinary Incontinence Short Form (ICIQ-UI SF).
The score ranges from 0 (no impact) to 21 (maximal impact).
|
Baseline, 3 months, 6 months, 12 months and 24 months after implantation
|
|
Evolution of Urinary Symptoms
Prazo: Baseline, 3 months, 6 months, 12 months, 24 months after implantation
|
Evolution of the Urinary Symptom Profile (USP).
The score ranges from 0 (no symptom) to 9 (maximal symptoms) for the subscore linked to the Stress Urinary Incontinence; from 0 (no symptom) to 21 (maximal symptoms) for the subscore linked to the overactive bladder; from 0 (no symptom) to 9 (maximal symptoms) for the subscore linked to the dysuria.
|
Baseline, 3 months, 6 months, 12 months, 24 months after implantation
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Nicolas Barry Delongchamps, MD, PHD, Hôpital Cochin, APHP, Université Paris Cité, Paris, France.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Urogenitais Masculinas
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Distúrbios da micção
- Sintomas do Trato Urinário Inferior
- Manifestações Urológicas
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Incontinencia urinaria
- Incontinência Urinária, Estresse
- Equipamento cirúrgico
- Equipamentos e suprimentos
- Próteses e implantes
- Órgãos artificiais
- Esfíncter urinário, artificial
Outros números de identificação do estudo
Outros números de identificação do estudo
- SPHIN-X
- 2025-A00257-42 (Outro identificador: ANSM)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .